Steven Dickman is a highly experienced CEO and consultant to biotechnology and life sciences companies based in Cambridge, MA. He founded CBT Advisors in 2003, and since then, he has worked with over three hundred private biotechnology and life sciences clients. Steven has a strong background in storytelling and strategy, with much of his work focusing on drafting business sections for NASDAQ IPOs. As of April 2020, fifty-nine clients have gone public with his guidance, raising a total of $3.6 billion.

Steven's past experience includes working as a venture capitalist with TVM Capital, where he invested in Sirna Therapeutics and bluebird bio. He has also worked as a freelance writer at Science magazine and the Munich Correspondent for Macmillan's Nature. Steven is a graduate of Princeton University and has studied at the Summer Science Program and Glen School in Ridgewood, NJ.

Steven is a highly sought-after speaker and moderator at international conferences on biotechnology and finance. He has spoken at events such as the BIO International Convention, Sachs Forum, BioEurope, and Biotech Showcase, among others. He is also a published author on Forbes.com, where he shares his insights and analysis on the biotechnology industry.

Steven's expertise includes business and scientific analysis, business, scientific, and medical communication, speaking, and moderating. He has worked extensively in indication areas such as immunology, cardiovascular, neurodegenerative, vaccines, oncology, anti-infectives, and gastro-intestinal. His activity areas include venture fundraising, medical devices, molecular diagnostics, genomic data analysis, biologics, and technology platforms for drug discovery.